Recent Posts
- Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
- Theranexus, Lyon Neuroscience Research Center and CERMEP announce the creation and funding of new joint public/ private laboratory “NeuroImaging for Drug Discovery” (NI2D)
- Amolyt Pharma announces research collaboration with PeptiDream
- The Food and Drug Administration (FDA) issues a favorable opinion on the preclinical development plan submitted by Theranexus and BBDF
- Presentation of the results of the phase IB Clinical study of THN201 for Alzheimer’s disease at the clinical trials on Alzheimer’s disease conference (CTAD)
Recent Comments